Specifically, the increasing level of ACE2 was linked to better prognosis in cancers in stages 2 to 4 of KIRC patients (All P < 0.05) but was not linked to better prognosis in cancer stage 1 patients (HR = 0.57, P=0.069, Table 1). The gene discussed is ACE2; the disease is cancer.